Table 2.
Sex distribution of Proteus mirabilis urinary tract infections in patients with urinary stones (%).
| Antibiotic | Total (n = 317) | Male (n = 115) | Female (n = 202) | p |
|---|---|---|---|---|
| Meropenem | 311 (98.1) | 111 (96.5) | 200 (99.0) | 0.257 |
| Imipenem | 305 (96.2) | 108 (93.9) | 197 (97.5) | 0.189 |
| Levofloxacin | 183 (57.7) | 56 (48.7) | 127 (62.9) | 0.014 |
| Cefuroxime | 161 (50.8) | 53 (46.1) | 108 (53.5) | 0.206 |
| Cefoxitin | 271 (85.5) | 93 (80.9) | 178 (88.1) | 0.078 |
| Ceftazidime | 276 (87.1) | 98 (85.2) | 178 (88.1) | 0.459 |
| Ceftriaxone | 196 (61.8) | 64 (55.7) | 132 (65.4) | 0.088 |
| Cefoperazone/Sulbactam | 304 (95.9) | 109 (94.8) | 195 (96.5) | 0.450 |
| Cefepime | 267 (84.2) | 93 (80.9) | 174 (86.1) | 0.178 |
| Amikacin | 314 (99.1) | 114 (99.1) | 200 (99.0) | 0.915 |
| Piperacillin/Tazobactam | 278 (87.7) | 97 (84.4) | 181 (89.6) | 0.171 |
| Sulfamethoxazole | 107 (33.8) | 48 (41.7) | 59 (29.2) | 0.023 |